妊娠期超重肥胖和子代代谢相关脂肪性肝病的Meta分析

吴玉莹; 恩卡尔·努尔; 王佑新; 王明月; 杨依凡; 杨树涵; 孙玲玲; 王辉

doi:10.16835/j.cnki.1000-9817.2025259

妊娠期超重肥胖和子代代谢相关脂肪性肝病的Meta分析

doi: 10.16835/j.cnki.1000-9817.2025259

吴玉莹^{1, 2},
恩卡尔·努尔^{1, 2},
王佑新^{1, 2},
王明月^{1, 2},
杨依凡^{1, 2},
杨树涵^{1, 2},
孙玲玲^{2, 3, ,},
王辉^{1, 2, ,}

1.
北京大学公共卫生学院妇幼卫生学系，北京 100191
2.
北京大学医学部-潍坊市妇幼健康联合研究中心
3.
潍坊市妇幼保健院产科

基金项目:

北京大学医学部-潍坊市妇幼健康联合研究中心科研基金项目 PKUWF-Y10

详细信息

作者简介:
吴玉莹(2001-)，女，河南信阳人，在读硕士，主要研究方向为妇幼健康影响因素及干预措施

通讯作者:
孙玲玲，E-mail：sllwf5620@163.com

王辉，E-mail：huiwang@bjmu.edu.cn

利益冲突声明 所有作者声明无利益冲突。
中图分类号: R179 R723.14 R714.255 Q485
计量
- 文章访问数: 16
- HTML全文浏览量: 13
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2025-02-14
- 修回日期: 2025-04-30
- 网络出版日期: 2025-08-30
- 刊出日期: 2025-08-25

Meta-analysis of maternal overweight/obesity during pregnancy and offspring metabolic dysfunction-associated steatotic liver disease

WU Yuying^{1, 2},
ENKAER Nuer^{1, 2},
WANG Youxin^{1, 2},
WANG Mingyue^{1, 2},
YANG Yifan^{1, 2},
YANG Shuhan^{1, 2},
SUN Lingling^{2, 3
, ,},
WANG Hui^{1, 2
, ,}

1.
Department of Maternal and Child Health, School of Public Health, Peking University, Beijing 100191, China

摘要

摘要: 目的评估妊娠期超重肥胖和子代代谢相关(非酒精性)脂肪性肝病(MASLD)发生风险之间的相关性，为生命早期预防MASLD提供理论依据。方法在线检索中国知网、万方数据知识服务平台、中国生物医学文献服务系统SinoMed和PubMed、Embase、Web of Science、Cochrane Library、PROSPERO、PQDT Global、ScienceDirect 10个数据库中有关妊娠期超重肥胖和子代MASLD发生关联的研究文献，检索时间为2014年1月至2024年12月。由2名研究者独立进行筛选文献、资料提取和质量评价，采用R 4.3.3软件进行统计分析。结果共纳入10篇文献，涉及10 229名研究对象，包括4篇队列研究和6篇病例对照研究。队列研究合并效应值显示妊娠期超重肥胖会增加子代MASLD发生风险(RR=1.59，95%CI=1.06~2.39，P < 0.05)，研究间存在中度异质性(I²=56.9%，P=0.07)；病例对照研究合并效应值显示妊娠期超重肥胖与子代MASLD的发生风险呈正相关(OR=2.00，95%CI=1.68~2.39，P < 0.05)，异质性较低(I²=48.8%，P=0.08)。结论妊娠期超重肥胖与子代MASLD的发生风险呈正相关，孕期体重管理可降低子代MASLD的发生风险。
- 妊娠 /
- 超重 /
- 肥胖症 /
- 脂肪肝 /
- Meta分析
Abstract: Objective To evaluates the association between maternal overweight/obesity during pregnancy and offspring risk of metabolic dysfunction-associated steatotic liver disease (MASLD), providing theoretical evidence for early-life MASLD prevention. Methods An online search was conducted across ten databases (CNKI, Wanfang, SinoMed, PubMed, Embase, Web of Science, Cochrane Library, PROSPERO, PQDT Global, ScienceDirect) for research literature on the association between maternal overweight/obesity during pregnancy and the development of MASLD in offspring, with the search period spanning from January 2014 to December 2024. Two researchers independently screened literature, extracted data, and assessed study quality. Statistical analysis was performed using R 4.3.3. Results Ten studies involving 10 229 participants were included, comprising 4 cohort studies and 6 case-control studies. Cohort studies showed that maternal overweight and obesity significantly increased offspring MASLD risk (RR=1.59, 95%CI=1.06-2.39, P < 0.05), with moderate heterogeneity (I²=56.9%, P=0.07). Case-control studies indicated a positive association between maternal overweight/obesity during pregnancy and offspring risk of MASLD(OR=2.00, 95%CI=1.68-2.39, P < 0.05), with low heterogeneity (I²=48.8%, P=0.08). Conclusions Maternal overweight/obesity during pregnancy positively correlates with offspring MASLD risk. Gestational weight management may reduce the risk.
- Pregnancy /
- Overweight /
- Obesity /
- Fatty liver /
- Meta-analysis
注释:

1) 利益冲突声明 所有作者声明无利益冲突。

HTML全文

图 1 妊娠期MOO与子代MASLD关联文献检索流程

Figure 1. Literature retrieval process for investigating the association between MOO and offspring MASLD

下载: 全尺寸图片幻灯片

图 2 队列研究中MOO与子代MASLD发生风险的Meta分析

Figure 2. Meta-analysis for cohort studies on the risk of MOO and offspring MASLD

下载: 全尺寸图片幻灯片

图 3 病例对照研究中MOO与子代MASLD发生风险的Meta分析

Figure 3. Meta-analysis for case control studies on the risk of MOO and offspring MASLD

下载: 全尺寸图片幻灯片

表 1 MOO与子代MASLD关系纳入文献的基本信息

Table 1. Basic information on the relationship between MOO and offspring MASLD selected in the literature

第一作者及年份	国家/地区	研究类型	结局指标	样本量	子代年龄/岁	RR/OR值(95%CI)	NOS总分
Zeng(2022)^[17]	中国	队列研究	NAFLD(CAP≥214.53 dB/m，肝脏超声)	430	8	1.19(1.09~1.29)	8
Geurtsen(2021)^[28]	荷兰	队列研究	NALFD(MRI)	2 168	10	1.52(0.90~2.58)	9
Bellatorre(2018)^[29]	美国	队列研究	NAFLD(肝脏脂肪分数≥5.56%)	254	16.4±1.5	2.79(0.91~8.54)	6
Patel(2016)^[18]	英国	队列研究	NAFLD(肝脏超声)	1 215	17.8±0.4	2.63(1.20~5.55)	7
Nairz(2024)^[21]	奥地利	病例对照研究	NAFLD(CAP值超过P₉₀，肝脏超声)	595	17	3.59(1.69~7.62)	7
De Ruyter(2024)^[22]	芬兰	病例对照研究	MAFLD(ALT超过2倍正常值上限)	460	2~16	1.16(0.68~1.99)	6
Abeysekera(2021)^[20]	英国	病例对照研究	NAFLD(CAP值≥248 dB/m，肝脏超声)	2 961	24	2.09(1.62~2.68)	9
Hagström(2021)^[19]	瑞典	病例对照研究	NAFLD(活检)	882	< 25	2.24(1.59~3.17)	7
Cantoral(2020)^[30]	墨西哥	病例对照研究	NAFLD(MRI)	97	21.4±0.5	1.79(1.51~2.14)	7
Ayonrinde(2018)^[31]	澳大利亚	病例对照研究	NAFLD(肝脏超声)	1 167	17	2.88(1.64~5.10)	7
注：既往研究提示，在成人中94.5%的NAFLD患者可归类为MASLD，具有较高的一致性^[32]；CAP为受控衰减参数(controlled attenuation parameter)，MRI为磁共振成像(magnetic resonance imaging)，ALT为丙氨酸氨基转移酶(alanine aminotransferase)。

下载: 导出CSV

参考文献(37)

[1]	OECD, WHO. Health at a glance: Asia/Pacific 2024[M]. Paris: OECD, 2024.
[2]	SOLMI F, MORRIS S. Overweight and obese pre-pregnancy BMI is associated with higher hospital costs of childbirth in England[J]. BMC Pregnancy Childbirth, 2018, 18(1): 253. doi: 10.1186/s12884-018-1893-z
[3]	CHEN C, XU X, YAN Y. Estimated global overweight and obesity burden in pregnant women based on panel data model[J]. PLoS One, 2018, 13(8): e0202183. doi: 10.1371/journal.pone.0202183
[4]	NORMAN J E, REYNOLDS R M. The consequences of obesity and excess weight gain in pregnancy[J]. Proceed Nutr Soc, 2011, 70(4): 450-456. doi: 10.1017/S0029665111003077
[5]	HESLEHURST N, NGONGALAH L, BIGIRUMURAME T, et al. Association between maternal adiposity measures and adverse maternal outcomes of pregnancy: systematic review and Meta-analysis[J]. Obesity Rev, 2022, 23(7): e13449. doi: 10.1111/obr.13449
[6]	BARBOUNI K, JOTAUTIS V, METALLINOU D, et al. When weight matters: how obesity impacts reproductive health and pregnancy: a systematic review[J]. Current Obes Reports, 2025, 14(1): 37. doi: 10.1007/s13679-025-00629-9
[7]	ZELJKOVIC A, VEKIC J, STEFANOVIC A. Obesity and dyslipidemia in early life: impact on cardiometabolic risk[J]. Metabolism, 2024, 156: 155919. doi: 10.1016/j.metabol.2024.155919
[8]	RIVERA-AGUIRRE J. Desarrollo temprano de hígado graso no alcohólico por exposición fetal a obesidad gestacional. Revisión de tema[J]. Med UIS, 2023, 36(3): 9-19.
[9]	范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510. FAN J G, XU X Y, NAN Y M, et al. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024)[J]. J Pract Hepatol, 2024, 27(4): 494-510. (in Chinese)
[10]	YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology (Baltimore, Md.), 2016, 64(1): 73-84. doi: 10.1002/hep.28431
[11]	耿坐涛, 张丹, 朱筱桐, 等. 儿童非酒精性脂肪性肝病危险因素的研究进展[J]. 中国儿童保健杂志, 2024, 32(4): 412-418. GENG Z T, ZHANG D, ZHU X T, et al. Risk factors of non-alcoholic fatty liver disease in children[J]. Chin Child Health Care, 2024, 32(4): 412-418. (in Chinese)
[12]	SCHWIMMER J B, DEUTSCH R, KAHEN T, et al. Prevalence of fatty liver in children and adolescents[J]. Pediatrics, 2006, 118(4): 1388-1393. doi: 10.1542/peds.2006-1212
[13]	VOS M B, ABRAMS S H, BARLOW S E, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN)[J]. J Pediatr Gastroenterol Nutr, 2017, 64(2): 319-334. doi: 10.1097/MPG.0000000000001482
[14]	SARKAR M, GRAB J, DODGE J L, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes[J]. J Hepatol, 2020, 73(3): 516-522. doi: 10.1016/j.jhep.2020.03.049
[15]	COCHRANE A L K, MURPHY M P, OZANNE S E, et al. Pregnancy in obese women and mechanisms of increased cardiovascular risk in offspring[J]. Europ Heart J, 2024, 45(48): 5127-5145. doi: 10.1093/eurheartj/ehae671
[16]	BAIRD J, JACOB C, BARKER M, et al. Developmental origins of health and disease: a lifecourse approach to the prevention of non-communicable diseases[J]. Healthcare (Basel), 2017, 5(1): 14.
[17]	ZENG J, SHEN F, ZOU Z Y, et al. Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring[J]. World J Gastroenterol, 2022, 28(16): 1681-1691. doi: 10.3748/wjg.v28.i16.1681
[18]	PATEL S, LAWLOR D A, CALLAWAY M, et al. Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease[J]. BMC Pediatr, 2016, 16: 47. doi: 10.1186/s12887-016-0585-y
[19]	HAGSTRÖM H, SIMON T G, ROELSTRAETE B, et al. Maternal obesity increases the risk and severity of NAFLD in offspring[J]. J Hepatol, 2021, 75(5): 1042-1048. doi: 10.1016/j.jhep.2021.06.045
[20]	ABEYSEKERA K W M, ORR J G, MADLEY-DOWD P, et al. Association of maternal pre-pregnancy BMI and breastfeeding with NAFLD in young adults: a parental negative control study[J]. Lancet Reg Health-Europ, 2021(10): 100206.
[21]	NAIRZ J, MESSNER A, KIECHL S J, et al. Determinants of non-alcoholic fatty liver disease in young people: maternal, neonatal, and adolescent factors[J]. PLoS One, 2024, 19(2): e0298800. doi: 10.1371/journal.pone.0298800
[22]	DE RUYTER H, AITOKARI L, LAHTI S, et al. Maternal gestational hypertension, smoking and pre-eclampsia are associated with metabolic dysfunction-associated fatty liver disease in overweight offspring[J]. Acta Obstetr Gynecol Scand, 2024, 103(6): 1183-1191. doi: 10.1111/aogs.14816
[23]	BRUMBAUGH D E, TEARSE P, CREE-GREEN M, et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes[J]. J Pediatr, 2013, 162(5): 930-936. doi: 10.1016/j.jpeds.2012.11.017
[24]	PAGE M J, MCKENZIE J E, BOSSUYT P M, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J]. BMJ, 2021, 372: n71.
[25]	RICHARDSON W S, WILSON M C, NISHIKAWA J, et al. The well-built clinical question: a key to evidence-based decisions[J]. ACP J Club, 1995, 123(3): A12-A13. doi: 10.7326/ACPJC-1995-123-3-A12
[26]	WELLS G, SHEA B, O'CONNELL D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Meta-analyses[EB/OL]. (2014)[2025-02-05]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
[27]	HIGGINS J P T, THOMPSON S G. Quantifying heterogeneity in a Meta-analysis[J]. Stat Med, 2002, 21(11): 1539-1558. doi: 10.1002/sim.1186
[28]	GEURTSEN M L, WAHAB R J, FELIX J F, et al. Maternal early-pregnancy glucose concentrations and liver fat among school-age children[J]. Hepatology, 2021, 74(4): 1902-1913.
[29]	BELLATORRE A, SCHERZINGER A, STAMM E, et al. Fetal overnutrition and adolescent hepatic fat fraction: the exploring perinatal outcomes in children study[J]. J Pediatr, 2018, 192: 165-170.
[30]	CANTORAL A, MONTOYA A, LUNA-VILLA L, et al. Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study[J]. Bjog Int J Obstetr Gynaecol, 2020, 127(10): 1200-1209.
[31]	AYONRINDE O T, ADAMS L A, MORI T A, et al. Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents[J]. Hepatology, 2018, 67(1): 108-122.
[32]	SONG R, LI Z, ZHANG Y, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults[J]. Liver Int, 2024, 44(4): 1051-1060.
[33]	NYASORDZI J, CONRAD J, GOLETZKE J, et al. Early life factors and their relevance for markers of cardiometabolic risk in early adulthood[J]. Nutr Metab Cardiovasc Dis, 2021, 31(7): 2109-2121.
[34]	PENG L, SHEN J, LI L, et al. Birthweight influences liver structure, function and disease risk: evidence of a causal association[J]. Diabetes Obes Metab, 2024, 26(11): 4976-4988.
[35]	EBRAHIMI F, YAO J, HAGSTROEM H, et al. Birth weight, gestational age, and risk of pediatric-onset MASLD[J]. JAMA Network Open, 2024, 7(9): e2432420.
[36]	KLEPPER C. Maternal nonalcoholic fatty liver disease: a driver of fetal hepatic steatosis?[D]. Cincinnati: University of Cincinnati, 2022.
[37]	MOURALIDARANE A, SOEDA J, LIN C I, et al. Maternal obesity during pregnancy and lactation programs development of non-alcoholic fatty liver disease in offspring fed a postnatal hyper-calorific diet[J]. Reprod Sci, 2011, 18(3): 216A.